Click the link below to access the glossary.
- Ultragenyx today announced a Phase 1/2 study of UX003 for MPS VII
- Synageva BioPharma joins the International MPS Network in support of MPS Awareness Day 2013
- Icahn School of Medicine at Mount Sinai and Bene Pharmachem Gmbh To Collaborate On Clinical Studies for Mucopolysaccharidoses
- LYSOGENE received US orphan drug designation for SAF-301 for treatment of MPS III A